title: Reply to: "Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling".
authors.forename: Charles D
authors.initials: CD
authors.lastname: Howell
authors.forename: Runyan
authors.initials: R
authors.lastname: Jin
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Dowling
mesh_terms: D005260:Female; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000821:virology*; D006801:Humans; D007378:Interleukins / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide
chemical_list: D007378:Interleukins